RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
  Adrenergics
  Analgesics
  Anti Cancer Drugs
  Anti-Clotting Drugs
  Anti-Inflammatory
  Antibiotics
  Anticholesterol
  Antihypertensives
  Antivirals
  Fatty Acids
  Hypnotics
  Metals
  PPI
  Surfactants
  Varenicline
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Pharmacology Channel

subscribe to Pharmacology newsletter
Latest Research : Pharmacology

   EMAIL   |   PRINT
New molecules that accelerate chemical reactions for manufacturing drugs

Aug 19, 2005 - 10:41:00 PM
"For more than a century, most catalysts were prepared using chemical compounds called phosphines," said Guy Bertrand, the lead author of the study and Distinguished Professor of chemistry. "But in the 1990s, carbenes were found to be useful to make catalysts. The new carbenes we have prepared in the laboratory are such that they protect the metals to which they bind, making the metal catalysts more stable and longer lasting."

 
[RxPG] Chemists at the University of California, Riverside have synthesized a new class of carbenes – molecules that have unusual carbon atoms – that is expected to have wide applications in the pharmaceutical industry, ultimately resulting in a reduction in the price of drugs.

Called cyclic alkyl amino carbenes or CAACs, the molecules attach themselves to metals, such as palladium, to form highly efficient catalysts that allow chemical transformations otherwise considered impossible. The carbenes modulate the properties of the metals to which they are bound and can facilitate and speed up reactions involving their use.

Study results appear in the Angewandte Chemie International Edition, and were published online Aug. 1.

A carbene is a molecule that has a carbon atom with six electrons instead of the usual eight. Because of the electron deficiency, carbenes are highly reactive and usually unstable in nature.

In their paper, the UCR chemists discuss a set of chemical reactions involving the use of catalysts other than those that are CAAC-based. The authors note that these catalysts need strong heating to be effective. They add that the CAAC-based catalysts, on the other hand, can be used not only at room temperature but also in smaller amounts than is necessary for the other catalysts.

"For more than a century, most catalysts were prepared using chemical compounds called phosphines," said Guy Bertrand, the lead author of the study and Distinguished Professor of chemistry. "But in the 1990s, carbenes were found to be useful to make catalysts. The new carbenes we have prepared in the laboratory are such that they protect the metals to which they bind, making the metal catalysts more stable and longer lasting."

Because nitrogen atoms stabilize a carbene when they are adjacent to it, chemists believed until now that two nitrogen atoms were necessary in a carbene to make efficient catalysts. But having two nitrogen atoms also imposes structural limitations at the center of the carbene.

The carbenes synthesized by the UCR chemists has only one nitrogen atom, which lends the molecule a far more flexible structure. In effect, the carbenes are bigger at the metallic center of the catalyst, a feature that improves the efficiency of the catalyst.

"We started this project nearly two years ago," said Vincent Lavallo, an undergraduate researcher in Bertrand's laboratory and the first author of the paper. "The carbene-based catalysts we report can simplify complex chemical preparations. Further, just mild temperatures are needed for the catalyst to be effective. Because of the catalyst's longevity, you need only a small amount to achieve your final product. All of this can dramatically reduce the cost of manufacturing drugs, given that pharmaceutical companies are increasingly using carbene-supported catalysts for their chemical reactions."

Bertrand's research group plans to continue to modify the new carbenes to find more efficient catalysts. "We're looking also for new catalytic reactions facilitated by these new carbene metal complexes," Lavallo said. "The CAACs have made the field of carbene chemistry more exciting than ever."



Publication: Study results appear in the Angewandte Chemie International Edition, and were published online Aug. 1.
On the web: University of California - Riverside 

Advertise in this space for $10 per month. Contact us today.


Related Pharmacology News
Palliative radiotherapy for bone metastases in elderly patients improves quality of life
Research shows promise for microwave ablation to relieve painful bone and soft-tissue tumors
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study suggests dexmedetomidine before surgery reduced remifentanil-induced hyperalgesia
Research examines effects of opioids on patients with sickle cell disease
Full range of treatment settings and their effects on radiofrequency heat lesion size
High-dose opioids disturb hormones long-term, but mental and physiologic function improves
Web-based tools found to enhance recruitment and prescreening for clinical pain trials
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study: Pain improves during first year but mental-health problems linger

Subscribe to Pharmacology Newsletter

Enter your email address:


 Additional information about the news article
Yves Canac, Carsten Präsang and Bruno Donnadieu of UCR assisted with the study. The National Institutes of Health and the chemicals manufacturer Rhodia provided support.

The University of California, Riverside is a major research institution and a national center for the humanities. Key areas of research include nanotechnology, genomics, environmental studies, digital arts and sustainable growth and development. With a current undergraduate and graduate enrollment of nearly 17,000, the campus is projected to grow to 21,000 students by 2010. Located in the heart of inland Southern California, the nearly 1,200-acre, park-like campus is at the center of the region's economic development. Visit www.ucr.edu or call 951 UCR-NEWS (827-6397) for more information. Media sources are available at http://mmr.ucr.edu/experts/.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)